SP-2-225 / Shuttle Pharma - LARVOL DELTA

Inhibition of HDAC6 enhanced radiation therapy induced antitumor response in melanoma (AACR 2024) - "The combination of conditioned M1 macrophages with an irradiated tumor microenvironment resulted in an increased M1/M2 ratio and infiltration of effector memory and central memory CD8 T-cells underscoring the influence of transplanted macrophages on the local antitumor immunity. Therefore, our findings demonstrate the ability of HDAC6 inhibitors to regulate macrophage function and phenotype as a cell therapy for use in combination with radiation therapy."

Melanoma • Oncology • Solid Tumor

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform (PRNewswire) - "Shuttle Pharmaceuticals Holdings, Inc...announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled 'Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.'...The Company's HDAC pre-clinical inhibitor platform includes: SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6; SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product; SP-1-303 is Shuttle Pharma's pre-clinical selective Class I HDAC inhibitor..."

Patent • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics (PRNewswire) - "Shuttle Pharmaceuticals Holdings...announced the publication of a manuscript reporting on the ability of Shuttle's lead Histone deacetylase 6 (HDAC6) inhibitor drug candidate (SP-2-225) to stimulate the innate immune system following radiation therapy....'The report highlights to the scientific and financial community how our novel selective inhibitor (SP-2-225) is able to target the HDAC6 function in tumors to inhibit tumor growth and enhance the M1/M2 ratio of infiltrating macrophages within tumors as a combination therapy with RT'..."

Preclinical • Oncology

Radiation therapy-induced immune response enhanced by selective HDAC6 Inhibition. (PubMed, Mol Cancer Ther) - "This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse post-radiation therapy."

Journal • Oncology

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates (PRNewswire) - "Shuttle Pharmaceuticals...today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model. The pre-clinical work outlined in the research agreement with Georgetown will support the Company's IND-enabling studies in 2023 with a goal to submit an investigational new drug application (IND) for the selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024."

IND • Licensing / partnership • New P1 trial • Breast Cancer • Oncology • Solid Tumor

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates (Investing.com) - “Shuttle Pharmaceuticals Holdings, Inc…announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model. The pre-clinical work outlined in the research agreement with Georgetown will support the Company's IND-enabling studies in 2023 with a goal to submit an investigational new drug application (IND) for the selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024.”

IND • Licensing / partnership • New P1 trial • Breast Cancer • Oncology • Solid Tumor